Cybin Reports Q1 FY26 Financial Results, Advances Key Milestones in Psychedelic Therapies

Cybin Inc. reported Q1 FY26 financial results and updated on key milestones. The company is advancing its lead clinical programs, CYB003 and CYB004, through multiple inflection points. CYB003 is being evaluated for the adjunctive treatment of major depressive disorder, with a Phase 3 study expected to enroll approximately 550 participants. The Phase 2 study for CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.